CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
TK-NEO is a personalized cancer vaccine targeting neoantigens in patients with advanced solid tumors. Utilizing a unique DNA synthesis method, it aims to enhance immune responses and prevent cancer relapse, with plans for clinical trials and eventual licensing to pharmaceutical companies.
TK-NEO is a DNA-based Neoantigen Cancer Vaccine (NCV), for use as therapeutic vaccination in patients with locally advanced or metastatic solid tumours. NCVs are a new form of precision medicine and are a perfect clinical approach for highly heterogeneous tumors in patients with metastatic disease.
Takis has developed and patented a unique method for production of patient-specific NCVs based on a 6-week process, from sequencing the specific tumour DNA, synthesis of the right DNA sequence for th…
TAKIS SRL
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
